The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis
Open accessAbstract
BACKGROUND: Behçet's disease is a multisystem vasculitis of unknown origin. Standard treatment mainly comprises systemic immunosuppressive agents. Ocular involvement, mostly posterior uveitis with retinal vasculitis, leads to blindness in 20-50% of the involved eyes within 5 years. The efficacy of interferon alfa-2a was studied in patients with sight threatening posterior uveitis or retinal vasculitis. METHODS: 50 patients were included in this open, non-randomised, uncontrolled prospective study. Recombinant human interferon alfa-2a (rhIFNalpha-2a) was applied at a dose of 6 million units subcutaneously daily. Dose reduction was performed according to a decision tree until discontinuation. Disease activity was evaluated every 2 weeks by the Behçet's disease activity scoring system and the uveitis scoring system. RESULTS: Response rate of the ocular manifestations was 92% (three non-responder, one incomplete response). Mean visual acuity rose significantly from 0.56 to 0.84 at week 24 (p<0.0001). Posterior uveitis score of the affected eyes fell by 46% every week (p<0.001). Remission of retinal inflammation was achieved by week 24. Mean Behçet's disease activity score fell from 5.8 to 3.3 at week 24 and further to 2.8 at week 52. After a mean observation period of 36.4 months (range 12-72), 20 patients (40%) are off treatment and disease free for 7-58 months (mean 29.5). In the other patients maintenance IFN dosage is three million units three times weekly. CONCLUSIONS: rhIFNalpha-2a is effective in ocular Behçet's disease, leading to significant improvement of vision and complete remission of ocular vasculitis in the majority of the patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Criteria for diagnosis of Behçet's disease
Weichsler, B., Davatchi, F., Lehner, T., O’Duffy, J. D., Rigby, A. S., & Gregory, J. K. (1990) · The Lancet · Cited by 3,082
Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.
(1990) · PubMed · Cited by 2,637
A Controlled Trial of Azathioprine in Behçet's Syndrome
Yazici, H., Pazarli, H., Barnes, C. G., Tüzün, Y., Özyazgan, Y., Silman, A., Serdaroğlu, S., Oğuz, V., Yurdakul, S., Lovatt, G. E., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002013220501 · Cited by 647
Behcet, H. (1937) · Medical Entomology and Zoology · Cited by 645
Masuda, K., Urayama, A., Kogure, M., Nakajima, A., Nakae, K., & Inaba, G. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92381-7 · Cited by 490
Autoimmunity after Alpha-Interferon Therapy for Malignant Carcinoid Tumors
Rönnblom, L. E., Alm, G. V., & Öberg, K. E. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-178 · Cited by 455
The neglected role of type I interferon in the T-cell response: implications for its clinical use
Belardelli, F., & Gresser, I. (1996) · Immunology Today · doi:10.1016/0167-5699(96)10027-x · Cited by 299
Interferon-Associated Retinopathy
Guyer, D. R. (1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090030068041 · Cited by 282
Azathioprine in Behçet's syndrome. Effects on long‐term prognosis
Hamuryudan, V., Özyazgan, Y., Hizli, N., Mat, C., Yurdakul, S., Tüzün, Y., Şlenocak, M., & Yazici, H. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400425 · Cited by 280
Transplantation of discordant xenografts: a challenge revisited
Parker, W., Saadi, S., Lin, S. S., Holzknecht, Z. E., Bustos, M., & Platt, J. L. (1996) · Immunology Today · doi:10.1016/0167-5699(96)10028-1 · Cited by 254
Preziati, D., La Rosa, L., Covini, G., Marcelli, R., Rescalli, S., Persani, L., Del Ninno, E., Meroni, P. L., Colombo, M., & Beck-Peccoz, P. (1995) · European Journal of Endocrinology · doi:10.1530/eje.0.1320587 · Cited by 226
Effectiveness of cyclosporin therapy for Beh¸let's disease
Nussenblatt, R. B., Palestine, A. G., Chan, C., Mochizuki, M., & Yancey, K. B. (1985) · Arthritis & Rheumatism · doi:10.1002/art.1780280611 · Cited by 188
Role of γδ T cells in pathogenesis and diagnosis of Behçet's disease
Hasan, A., Fortune, F., Wilson, A., Warr, K., Lehner, T., Sanderson, J., Shinnick, T., Mizushima, Y., van der Zee, R., & Stanford, M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90868-5 · Cited by 175
Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders
Wandl, U. B., Nagel-Hiemke, M., May, D., Kreuzfelder, E., Kloke, O., Kranzhoff, M., Seeber, S., & Niederle, N. (1992) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(92)90250-r · Cited by 165
Anterior Ischemic Optic Neuropathy Secondary to Interferon Alfa
Purvin, V. A. (1995) · Archives of Ophthalmology · doi:10.1001/archopht.1995.01100080093034 · Cited by 107
BenEzra, D., Forrester, J. V., Nussenblatt, R. B., Tabbara, K. F., & Timonen, P. (1991) · Springer eBooks · doi:10.1007/978-3-642-77174-3 · Cited by 85
Bang, D. (1997) · Yonsei Medical Journal · doi:10.3349/ymj.1997.38.6.401 · Cited by 75
Efficacy and safety of systemic recombinant interferon‐alpha in Behcet's disease
Georgiou, Monastirli, Pasmatzi, Gartaganis, Goerz, & Tsambaos (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00159.x · Cited by 63
Interferon therapy for Behçet's disease
Alpsoy, E., Yılmaz, E., & Başaran, E. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(94)70226-8 · Cited by 55
Autoantibodies during α‐interferon therapy for chronic hepatitis B
Fattovich, G., Betterle, C., Brollo, L., Pedini, B., Giustina, G., Realdi, G., Alberti, A., & Ruol, A. (1991) · Journal of Medical Virology · doi:10.1002/jmv.1890340212 · Cited by 52
Eguchi, K., Kawakami, A., NAKASHIMA, M., Ida, H., Sakito, S., Matsuoka, N., Terada, K., Sakai, M., Kawabe, Y., Fukuda, T., et al. (1992) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1992.tb06470.x · Cited by 44
[Ocular prognosis in Behçet's disease].
Cochereau, I., Wechsler, B., LeHoang, P., Huong, D. U. L. T., Girard, B., Rousselie, F., & Godeau, P. (1992) · PubMed · Cited by 41
Review : The concurrence of lupus and fibromyalgia: implications for diagnosis and management
Bennett, R. M. (1997) · Lupus · doi:10.1177/096120339700600603 · Cited by 24
Cited by
EULAR recommendations for the management of Behçet disease
Hatemi, G., Silman, A., Bang, D., Bodaghi, B., Chamberlain, A. M., Gul, A., Houman, M. H., Kötter, I., Olivieri, I., Salvarani, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080432 · Cited by 718
Uveitis in Behçet disease: An analysis of 880 patients
Tugal-Tutkun, I., Onal, S., Altan-Yaycioglu, R., Huseyin Altunbas, H., & Urgancioglu, M. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.03.022 · Cited by 631
Current Concepts in the Etiology and Treatment of Behçet Disease
Evereklioglu, C. (2005) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2005.04.009 · Cited by 393
Current Concepts in the Etiology and Treatment of Behçet Disease
Androudi, S. (2006) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2005.12.006 · Cited by 333
Behçet's disease – a contemporary review
Mendes, D., Correia, M., Barbedo, M., Vaio, T., Mota, M., Gonçalves, O., & Valente, J. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.02.011 · Cited by 320
Metadata
- Authors
- Kotter, I.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2003-04-01
- Volume
- 87
- Issue
- 4
- Pages
- 423-431
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2170726975
- Cited by
- 274
- References
- 23
- FWCI
- 23.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.